BioCentury
ARTICLE | Clinical News

Astex Pharmaceuticals preclinical data

August 12, 2013 7:00 AM UTC

In a mouse xenograft model of melanoma with BRAF V600E mutations, AT13387 plus Zelboraf vemurafenib prevented tumor regrowth and delayed the emergence of resistant tumors compared to Zelboraf alone. Additionally, Astex said tumors that became resistant to Zelboraf alone remained sensitive to treatment with AT13387. Data were presented at the World Congress of Melanoma in Hamburg. Astex said a clinical study to evaluate AT13387 in combination with both BRAF and MEK inhibitors is being planned, but did not disclose details. The small molecule inhibitor of heat shock protein 90 (Hsp90) is in Phase I/II testing to treat non-small cell lung cancer (NSCLC) and castration-resistant prostate cancer (CRPC) and Phase II testing to treat gastrointestinal stromal tumors (GIST). ...